ADMA Biologics Inc ADMA:NASDAQ

Last Price$1.38NASDAQ Previous Close - Last Trade as of 4:00PM ET 11/30/21

Today's Change-0.07(4.83%)
Bid (Size)$1.37 (31)
Ask (Size)$1.40 (5)
Day Low / High$1.37 - 1.45
Volume1.4 M
 

View Biotechnology IndustryPeer Comparison as of 11/30/2021

 

ADMA Biologics Inc ( NASDAQ )

Price: $1.38
Change: -0.07 (4.83%)
Volume: 1.4 M
4:00PM ET 11/30/2021
 
 

Applied Therapeutics Inc ( NASDAQ )

Price: $11.48
Change: +0.70 (6.49%)
Volume: 118.6 K
4:00PM ET 11/30/2021
 
 

ZIOPHARM Oncology Inc ( NASDAQ )

Price: $1.39
Change: +0.10 (7.75%)
Volume: 3.4 M
4:00PM ET 11/30/2021
 
 

Fortress Biotech Inc ( NASDAQ )

Price: $2.85
Change: +0.06 (2.15%)
Volume: 2.00
4:00PM ET 11/30/2021
 
 

Cymabay Therapeutics Inc ( NASDAQ )

Price: $3.31
Change: -0.15 (4.34%)
Volume: 1.5 M
4:00PM ET 11/30/2021
 

Read more news Recent News

Update: ADMA Biologics Q3 Loss Narrows as Sales Rise; Raymond James Lifts Stock Rating -- Shares Soar Thursday Afternoon
2:10PM ET 11/11/2021 MT Newswires

(Updates with the analyst upgrade and stock move in the last two paragraphs.) ADMA Biologics (ADMA) late Wednesday reported a Q3 loss of $0.13 per share,...

Sector Update: Health Care Stocks Inch Higher in Premarket Thursday
8:55AM ET 11/11/2021 MT Newswires

Health care stocks were higher ahead of Thursday's market open. The Health Care SPDR (XLV) added 0.1% and the iShares NASDAQ Biotechnology Index (IBB) rose...

--Raymond James Upgrades ADMA Biologics to Strong Buy From Outperform; Keeps Price Target at $5
8:38AM ET 11/11/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care
8:21AM ET 11/11/2021 MT Newswires

Health care stocks were muted ahead of Thursday's market open. The Health Care SPDR (XLV) was up 0.1% and the iShares NASDAQ Biotechnology Index (IBB) was...

View all Commentary and Analysis

ADMA Biologics: Turning A Corner
2:01PM ET 11/20/2021 Seeking Alpha

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q3 2021 Results - Earnings Call Transcript
8:41PM ET 11/10/2021 Seeking Alpha

ADMA: Insiders Showing Their Cards
6:02PM ET 11/02/2021 Seeking Alpha

ADMA Biologics: Recent Significant Developments And Their Implications For The Stock
8:39AM ET 8/22/2021 Seeking Alpha

Company Profile

Business DescriptionADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Ramsey, NJ. View company web site for more details
Address465 State Route 17 South
Ramsey, New Jersey 07446-2012
Phone+1.201.478.5552
Number of Employees318
Recent SEC Filing11/16/20218-K
President, Chief Executive Officer & DirectorAdam S. Grossman
Chief Financial Officer & Executive Vice PresidentBrian Lenz
Vice President-Compliance & Clinical OperationsKaitlin Kestenberg
Senior Director-Scientific & Data AnalysisLucy DeMario

Company Highlights

Price Open$1.43
Previous Close$1.38
52 Week Range$1.01 - 3.11
Market Capitalization$270.2 M
Shares Outstanding195.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.65
Beta vs. S&P 500N/A
Revenue$17.0 M
Net Profit Margin-108.60%
Return on Equity-71.69%

Analyst Ratings as of 11/20/2021

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset